ALX Oncology Holdings Inc. Common Stock
$1.70
-$0.04 (-2.30%)
$1.67Day Range$1.75
Key Statistics
Market Cap
$235.07M
Shares Outstanding
138.3M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Jul 17, 2020
Round Lot
100
Locale
US
Trading Data
Day Open
$1.74
Day High
$1.75
Day Low
$1.67
Volume
5.06M
VWAP
$1.70
Prev Close
$1.74
Transactions
--
Acc. Volume
--
About ALX Oncology Holdings Inc. Common Stock
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
PHARMACEUTICAL PREPARATIONSSIC 283448 employees323 ALLERTON AVENUE, SOUTH SAN FRANCISCO, CA, 94080650-466-7125IPO Jul 17, 2020US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001810182
- Composite FIGI
- BBG00VR8SDG8
- Share Class FIGI
- BBG00VR8SF73
- Ticker Root
- ALXO
- SIC Code
- 2834
About ALX Oncology Holdings Inc. Common Stock (ALXO) Stock
ALX Oncology Holdings Inc. Common Stock (ALXO) closed the 2026-09-18 session at $1.70, down 2.30% versus the previous close (-0.04). The stock opened at $1.74 and traded between $1.67 and $1.75 during that session. Session trading volume was 5.1M shares. The volume-weighted average price (VWAP) is $1.70.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
ALX Oncology Holdings Inc. Common Stock has a market capitalization of $235.1 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. ALXO is listed on the XNAS exchange. The company employs approximately 48 people. ALX Oncology Holdings Inc. Common Stock is headquartered in SOUTH SAN FRANCISCO, CA. The recorded listing date is 2020-07-17.
On this page you can find market ALXO stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.